190 related articles for article (PubMed ID: 28045603)
21. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.
Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular adenoma: cost-effectiveness of different treatment strategies.
van der Sluis FJ; Bosch JL; Terkivatan T; de Man RA; Ijzermans JN; Hunink MG
Radiology; 2009 Sep; 252(3):737-46. PubMed ID: 19717753
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Treatment Strategies for Spinal Metastases.
Kowalchuk RO; Mullikin TC; Kim DK; Morris JM; Ebner DK; Harmsen WS; Merrell KW; Beriwal S; Waddle MR; Kim H
Pract Radiat Oncol; 2022; 12(3):236-244. PubMed ID: 35045365
[TBL] [Abstract][Full Text] [Related]
27. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy.
Aronsson M; Walfridsson H; Janzon M; Walfridsson U; Nielsen JC; Hansen PS; Johannessen A; Raatikainen P; Hindricks G; Kongstad O; Pehrson S; Englund A; Hartikainen J; Mortensen LS; Levin LÅ
Europace; 2015 Jan; 17(1):48-55. PubMed ID: 25341739
[TBL] [Abstract][Full Text] [Related]
28. Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective.
Ray CE; Battaglia C; Libby AM; Prochazka A; Xu S; Funaki B
J Vasc Interv Radiol; 2012 Mar; 23(3):306-14. PubMed ID: 22277271
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
32. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
[TBL] [Abstract][Full Text] [Related]
35. Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
Wu X; Uhlig J; Blasberg JD; Gettinger SN; Suh RD; Solomon SB; Kim HS
J Vasc Interv Radiol; 2022 Aug; 33(8):964-971.e2. PubMed ID: 35490932
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.
Wang L; Ke Q; Huang Q; Shao L; Chen J; Wu J
Int J Hyperthermia; 2020; 37(1):1313-1321. PubMed ID: 33243024
[TBL] [Abstract][Full Text] [Related]
37. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
Sieg M; Hartmann M; Settmacher U; Arefian H
BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
39. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis.
Pandharipande PV; Gervais DA; Mueller PR; Hur C; Gazelle GS
Radiology; 2008 Jul; 248(1):169-78. PubMed ID: 18458248
[TBL] [Abstract][Full Text] [Related]
40. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
Spolverato G; Vitale A; Ejaz A; Kim Y; Maithel SK; Cosgrove DP; Pawlik TM
World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
